CoChat

AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery

Open access
Koponen, Sanna, Kokki, Emmi, Tamminen, Toni, Ylä-Herttuala, Seppo · 2023 · Frontiers in Drug Delivery

The DOI matches its Crossref record; 78 of the 82 references it cites were found in a registry or an index; 6 of the 66 sources its claims cite were checked for support.

Abstract

Introduction: The eye is an excellent target for gene therapy because of its anatomical features. Gene therapy to treat ocular disorders relies on efficient gene delivery and transgene expression in the target cells. The aim of this study was to compare the biodistribution and safety of two different AAV serotypes after intravitreal (IVT) and subretinal injections. Methods: AAV2 (1 × 1012 vg/mL) and AAV9 (5 × 1012 vg/mL) vectors expressing an enhanced green fluorescent protein (EGFP) and an AAV9-empty (6 × 1011 vg/mL) vector were injected intravitreally or subretinally into both eyes of adult C57Bl/OlaHsd mice. The biodistribution of the viral vectors in the eye and off-target tissues was studied using qPCR. GFP expression was studied from cryosections, and GFP transduction efficacy was verified using immunohistostaining for GFP. In addition, electroretinography (ERG) was used to assess the effect of vectors on retinal function. Results: In addition to the eyes, viral vector copies were found in distant off-target tissues such as the liver, especially after AAV9-EGFP IVT and subretinal injections. AAV9-EGFP injections showed more GFP expression throughout the retina compared to AAV2-EGFP. AAV2-EGFP IVT showed transgene expression mainly in the ganglion cell layer, whereas subretinal injection showed GFP expression in the retinal pigment epithelium. In addition, GFP was expressed at a moderate level in the liver after both injection routes of AAV9 and in parts of the brain after all injection groups except AAV9-empty. Lowered a- and b-amplitude values were seen in ERG in both scotopic and photopic experiments after AAV9-EGFP subretinal injection compared to all other groups. Discussion: This study shows that intraocular injection of AAV2 and AAV9 transduces retinal cells. Although the more efficient transduction of the retina, negative effect on the retinal function, and off-target transgene expression of AAV9 makes AAV2 a more suitable gene delivery vector to treat ocular disorders.

Overview

CoChat Summary

TL;DR

AAV9-EGFP transduced the mouse retina more efficiently than AAV2-EGFP after both intravitreal and subretinal injection, but AAV9 also produced more off-target expression and reduced retinal function after subretinal delivery. The authors conclude AAV2 is a more suitable vector for ocular gene therapy.

Key findings

  • AAV9-EGFP IVT and subretinal injections transduced approximately 30%–40% of the retina; AAV2-EGFP IVT transduced approximately 10%, and AAV2-EGFP subretinal injection approximately 2%.
  • AAV2-EGFP IVT mainly transduced the ganglion cell layer, whereas AAV2-EGFP subretinal injection mainly transduced the RPE; AAV9-EGFP transduced throughout the retina after both routes.
  • Vector copies were found in distant tissues, especially the liver after AAV9-EGFP IVT and subretinal injections. GFP was expressed at a moderate level in the liver after both AAV9 routes and in parts of the brain after all groups except AAV9-empty.
  • AAV9-EGFP subretinal injection lowered a- and b-wave amplitudes in scotopic and photopic ERG compared with other groups; scotopic a-wave p < 0.05 vs naive and p < 0.01 vs the rest, scotopic b-wave p < 0.05 vs naive and p < 0.01 vs the rest, and photopic b-wave p < 0.05 vs AAV9 IVT. It also caused retinal detachment and folding.

Methods

  • AAV2-EGFP (1 × 10^12 vg/mL), AAV9-EGFP (5 × 10^12 vg/mL), and AAV9-empty (6 × 10^11 vg/mL) were injected intravitreally or subretinally into both eyes of adult C57Bl/OlaHsd mice; 2 µL was given per eye.
  • Thirty-one male C57BL/6JOlaHsd mice aged 14–19 weeks were used; mice were euthanized 1 month after injection, and eyes, brain, lung, heart, liver, spleen, kidneys, testicles, lymph nodes, and quadriceps muscles were harvested.
  • Biodistribution was assessed by qPCR for WPRE copies per microgram genomic DNA; GFP expression was assessed from cryosections and immunohistostaining; retinal function was assessed by scotopic and photopic ERG, with two-way ANOVA and Bonferroni correction (p < 0.05 significant).

Limitations

  • The paper does not include a dedicated limitations section.
  • Limitations evident from the text include the use of only male mice, a single 1-month post-injection timepoint, and a rodent model whose thinner inner limiting membrane differs from humans and larger animals.
  • The text also notes that GFP immunogenicity/toxicity and the subretinal injection procedure itself may contribute to morphological changes, which could confound interpretation of safety and ERG results.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fddev.2023.1148795

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Figures

FIGURE 1 Fluorescence images showing EGFP in the eye after 1 month of AAV2-EGFP (1 × 1012 vg/mL) IVT (A) and subretinal injection (B), and after AAV9-EGFP (5 × 1012 vg/mL) IVT (C) and subretinal injection (D). GFP, green; Dapi, blue; IVT, intravitreal injection; SR, subretinal injection.
FIGURE 1 Fluorescence images showing EGFP in the eye after 1 month of AAV2-EGFP (1 × 1012 vg/mL) IVT (A) and subretinal injection (B), and after AAV9-EGFP (5 × 1012 vg/mL) IVT (C) and subretinal injection (D). GFP, green; Dapi, blue; IVT, intravitreal injection; SR, subretinal injection.CC BY · PubMed Central
FIGURE 2 Representative image of EGFP expression in the brain (A) 1 month after AAV2-EGFP (1 × 1012 vg/mL) IVT injection. The white box indicates the GFP-positive area. ×10 magnification of the GFP positive area (B). GFP, green; DAPI, blue.
FIGURE 2 Representative image of EGFP expression in the brain (A) 1 month after AAV2-EGFP (1 × 1012 vg/mL) IVT injection. The white box indicates the GFP-positive area. ×10 magnification of the GFP positive area (B). GFP, green; DAPI, blue.CC BY · PubMed Central
FIGURE 3 Representative images of EGFP expression in off-target tissues 1 month after AAV2-EGFP (1 × 1012 vg/mL) and AAV9-EGFP (5 × 1012 vg/mL) intraocular injections. EGFP expression in the liver after AAV9-EGFP IVT (A) and AAV2-EGFP subretinal injection (B), the heart after AAV9-EGFP IVT injection (C), the kidney after AAV2-EGFP IVT injection (D), the spleen after AAV9-EGFP IVT injection (E), and the testicle after AAV9-EGFP IVT injection (F). GFP, green; Dapi, blue; IVT, intravitreal injection; SR, subretinal injection.
FIGURE 3 Representative images of EGFP expression in off-target tissues 1 month after AAV2-EGFP (1 × 1012 vg/mL) and AAV9-EGFP (5 × 1012 vg/mL) intraocular injections. EGFP expression in the liver after AAV9-EGFP IVT (A) and AAV2-EGFP subretinal injection (B), the heart after AAV9-EGFP IVT injection (C), the kidney after AAV2-EGFP IVT injection (D), the spleen after AAV9-EGFP IVT injection (E), and the testicle after AAV9-EGFP IVT injection (F). GFP, green; Dapi, blue; IVT, intravitreal injection; SR, subretinal injection.CC BY · PubMed Central
FIGURE 4 Representative images of EGFP immunostaining of positive cells (black arrow) after the IVT or subretinal injection of AAV9-EGFP (5 × 1012 vg/mL) and AAV2-EGFP (1 × 1012 vg/mL). GFP in the liver after AAV9-EGFP IVT injection (A) and after AAV2-EGFP IVT injection (B). In the heart after AAV9-EGFP subretinal injection (C) and after AAV2-EGFP IVT injection (D). In the spleen after subretinal injection of AAV2-EGFP (E) and AAV9-EGFP (F). IVT, intravitreal injection; SR, subretinal injection.
FIGURE 4 Representative images of EGFP immunostaining of positive cells (black arrow) after the IVT or subretinal injection of AAV9-EGFP (5 × 1012 vg/mL) and AAV2-EGFP (1 × 1012 vg/mL). GFP in the liver after AAV9-EGFP IVT injection (A) and after AAV2-EGFP IVT injection (B). In the heart after AAV9-EGFP subretinal injection (C) and after AAV2-EGFP IVT injection (D). In the spleen after subretinal injection of AAV2-EGFP (E) and AAV9-EGFP (F). IVT, intravitreal injection; SR, subretinal injection.CC BY · PubMed Central
FIGURE 5 HE-stained eye sections after 1 month of intraocular injections of AAV2-EGFP (1 × 1012 vg/mL) (A,B), AAV9-EGFP (5 × 1012 vg/mL) (C,D), and AAV9-empty (6 × 1011 vg/mL) (E,F); black arrow indicates abnormal morphology seen in the retina. IVT, intravitreal injection; SR, subretinal injection.
FIGURE 5 HE-stained eye sections after 1 month of intraocular injections of AAV2-EGFP (1 × 1012 vg/mL) (A,B), AAV9-EGFP (5 × 1012 vg/mL) (C,D), and AAV9-empty (6 × 1011 vg/mL) (E,F); black arrow indicates abnormal morphology seen in the retina. IVT, intravitreal injection; SR, subretinal injection.CC BY · PubMed Central
FIGURE 6 Viral vector copy numbers per total genomic DNA in the eye and optic nerve samples 1 month after the IVT and subretinal injections of AAV2- and AAV9-EGFP (A) and in other tissues (B).
FIGURE 6 Viral vector copy numbers per total genomic DNA in the eye and optic nerve samples 1 month after the IVT and subretinal injections of AAV2- and AAV9-EGFP (A) and in other tissues (B).CC BY · PubMed Central
FIGURE 7 Scotopic ERG results. (A) The AAV9 subretinal group had significantly reduced ERG a-wave amplitudes than any other group. (B) Similarly, the b-wave amplitudes of the AAV9 subretinal group were significantly reduced in comparison to other groups. (C) The b-wave peak time was the shortest among the AAV9 subretinal group. On the contrary, the no-injection group had significantly prolonged peak time as compared to any other group. (D) Averaged raw ERG signals of each group at a flash intensity of 0.03 Cd × s/m2. (E) Filtered (5th order low-pass Bessel filter with a cut-off at 60 Hz) ERG signals of the same responses as in (D).
FIGURE 7 Scotopic ERG results. (A) The AAV9 subretinal group had significantly reduced ERG a-wave amplitudes than any other group. (B) Similarly, the b-wave amplitudes of the AAV9 subretinal group were significantly reduced in comparison to other groups. (C) The b-wave peak time was the shortest among the AAV9 subretinal group. On the contrary, the no-injection group had significantly prolonged peak time as compared to any other group. (D) Averaged raw ERG signals of each group at a flash intensity of 0.03 Cd × s/m2. (E) Filtered (5th order low-pass Bessel filter with a cut-off at 60 Hz) ERG signals of the same responses as in (D).CC BY · PubMed Central
FIGURE 8 Photopic ERG results. (A) The AAV9 subretinal group had statistically lower b-wave amplitudes than the AAV9 IVT and the AAV2 IVT groups. (B) The b-wave peak time was the shortest in the AAV9 subretinal group. On the contrary, the no-injection group had a significantly prolonged peak time in comparison to any other group. (C) Averaged raw ERG signals of each group at a flash intensity of 10 Cd × s/m2. (D) Filtered (5th order low-pass Bessel filter with a cut-off at 60 Hz) ERG signals of the same responses as in (C).
FIGURE 8 Photopic ERG results. (A) The AAV9 subretinal group had statistically lower b-wave amplitudes than the AAV9 IVT and the AAV2 IVT groups. (B) The b-wave peak time was the shortest in the AAV9 subretinal group. On the contrary, the no-injection group had a significantly prolonged peak time in comparison to any other group. (C) Averaged raw ERG signals of each group at a flash intensity of 10 Cd × s/m2. (D) Filtered (5th order low-pass Bessel filter with a cut-off at 60 Hz) ERG signals of the same responses as in (C).CC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 0 Not valid · 36 Not checked · 82 Own results and interpretations

72 more claims

Create a free account to see all 124 claims and to verify the 60 references still open.

See all claims — free account
  • Probably not a substantial claim. 34
  • It may state two separate claims as one. 19

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 78 references

Research works printed but not linked: 1

  1. Perlman, 1995, The electroretinogram: Erg

Cited by

See all 21

Metadata

Authors
Koponen, S., Kokki, E., Tamminen, T., & Ylä-Herttuala, S.
Affiliations
University of Eastern Finland (FI)
Venue
Frontiers in Drug Delivery
Published
2023-07-12
Volume
3
Pages
1148795-1148795
ISSN
2674-0850 (ISSN-L)
OpenAlex
W4384071789
Cited by
21
References
82
Citations by year
2026: 9 · 2025: 8 · 2024: 4
FWCI
3.49
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Drug Delivery (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Mary och Georg C. Ehrnrooths Stiftelse
  • Silmäsäätiö
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
AAV2, AAV9, adeno-associated virus serotypes, ocular gene therapy, intravitreal injection, subretinal injection, retinal transduction, transgene expression, tissue distribution, retinal function, electroretinogram, retinal pigment epithelium, retinal ganglion cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery. https://app.cochat.ai/papers/10.3389/fddev.2023.1148795
The paper
Koponen, S., Kokki, E., Tamminen, T., & Ylä-Herttuala, S. (2023). AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery. Frontiers in Drug Delivery. https://doi.org/10.3389/fddev.2023.1148795

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.